INTRODUCTION AND OBJECTIVES: Infected semen fuels the HIV pandemic. Despite the development of highly effective anti-retroviral drugs, more than 30,000 new cases are diagnosed annually in the U.S., only a 10% drop since 2005. Although it is recognized that semen infection is compartmentalized from blood, little is known about infection sites or effective treatment for semen HIV. To begin to develop treatment guidelines to eliminate HIV from semen, we have examined semen virus detection according to treatment regimen of HIV-infected men.
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METHODS: Review of a recently compiled blinded dataset of antiretroviral drug therapy, blood levels of HIV RNA and CD4+ lymphocytes, and HIV RNA or HIV proviral DNA in semen specimens submitted by 230 HIV-infected men undergoing semen screening from 2012 to 2015. Semen HIV was detected by RT-PCR.
RESULTS: All men on antiretroviral therapy had undetectable levels of HIV RNA in blood. Overall, 112 (18%) of the specimens tested positive for virus, with 81 (35%) of men producing at least one positive specimen. Ten of fourteen men not on antiretroviral therapy because of persistently low blood virus levels produced at least one positive semen specimen with 13 (36%) of 36 specimens testing positive for HIV. Average CD 4 blood count (634) for men producing positive semen specimens was not significantly different from those producing no HIVpositive semen specimens (683). Twenty eight (20%) of the 137 men taking combinations of reverse transcriptase inhibitors produced at least one HIV-positive semen specimen; of the total of 403 specimens in this treatment group, 74 (18%) were positive. Nine (23%) of the 39 men whose treatment regimen included a protease inhibitor produced at least one positive specimen, with only 11 (10%) of the total of 107 specimens in this group testing HIV positive. Eighteen (41%) of the 44 men whose treatment included an integrase inhibitor with no protease inhibitor produced at least one positive specimen, with 23 (18%) of the total of 128 specimens testing HIV positive.
CONCLUSIONS: Current antiretroviral treatment strategies do not eliminate HIV from semen as effectively as they eliminate HIV RNA in blood. These findings suggest anti-viral combinations containing a protease inhibitor may be more effective in reducing HIV in semen. A larger study cohort is urgently needed to test this possibility. METHODS: Between January 2016 and December 2016, 56 patients were entered into this study with symptoms of an UTI, 44 patients completed the study. All subjects completed a standardized UTI symptom score questionnaire on day 0-7 and day 14. Twenty-two volunteers were entered as controls in this study without symptoms of a urinary tract infection. The Level 1 Panel as a quantitative real-time Polymerase chain reaction (PCR) test for bacteria and fungi and the Level 2 test which detects virtually all microbial organisms and fungal pathogens were used versus routine culture and sensitivity test.
RESULTS: The symptom scores were statistically significantly better for those patients whose diagnosis and treatment was based on DNA results versus traditional culture studies. For instance, all 44 patients showed positive results in DNA sequencing tests, while only 13/ 44 patients had positive urine culture tests. The difference in average improvement of 8.5 is highly significant (p<0.0001) (Fig.1) . Especially in the cohort of patients with DNA positive test and culture negative the treatment outcomes were improved with respect to symptom scores when they started treatment on day 8. That ultimately led to faster recovery times and decreased the cost of treatment. Advantages of the DNA test also include an increased sensitivity for the diagnosis of anaerobic flora.
CONCLUSIONS: In this study DNA testing demonstrated a more accurate diagnosis of UTI than standard urine culture tests. In addition, DNA next generation testing led to better treatment outcomes in patients treated with antibiotics for primary anaerobic, aerobic or a combination of bacteria. Therefore, DNA testing allowed for the improved diagnosis and treatment based on symptoms of a UTI especially when urine cultures are negative. . 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e603
